Physician profile
Lee W Klepper
NPI 1649268004
$2,980.58
in general payments reported to CMS, 2019-2025
23 companies · $583 in 2025
The $583 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $319 · 2021: $546 · 2022: $561 · 2023: $576 · 2024: $266 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.78 | 2020-2025 | Xifaxan |
| Gilead Sciences, INC. | $193.92 | 2019-2023 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $149.49 | 2019-2023 | Entyvio |
| Madrigal Pharmaceuticals | $142.32 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $137.95 | 2025 | Axios |
| Novo Nordisk INC | $107.91 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $97.89 | 2020-2023 | Sutab |
| Abbott Laboratories | $93.13 | 2024 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $51.89 | 2020 | |
| Pfizer INC. | $41.60 | 2024 | |
| Medtronic, INC. | $37.84 | 2023-2024 | Interstim, Intellis Adaptivestim |
| Qol Medical, LLC | $36.20 | 2023 | Sucraid |
| Lilly USA, LLC | $21.55 | 2025 | Zepbound, Mounjaro |
| Ferring Pharmaceuticals INC. | $20.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $18.93 | 2024 | Omnipod |
| Corcept Therapeutics | $16.72 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $16.62 | 2025 | |
| Echosens North America, INC. | $15.37 | 2019 | |
| Janssen Biotech, INC. | $14.04 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $13.89 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.73 | 2024 | Gvoke Hypopen |
| Micro-Tech Endoscopy USA, INC. | $9.27 | 2024 | Lockado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Klepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.